Key result
Intravenous infusion of MoAb 60.3 at 2 mg/kg during occlusion reduced infarct size by 33% and 45% following 6 and 24 hours of reperfusion in a ferret model.
Why the study?
Does MoAb 60.3 reduce infarct size in a ferret model of myocardial ischemia and reperfusion?
Does MoAb 60.3 reduce infarct size in a ferret model of myocardial ischemia and reperfusion?
Effect estimate: 33% and 45% reduction
Inhibition of neutrophil function with MoAb 60.3 reduces myocardial infarct size in a ferret model when administered during ischemia, but efficacy is significantly reduced if delayed until reperfusion.
No takes yet. Share an insight, caveat, or question.
May support early neutrophil inhibition in ischemia-reperfusion models; hypothesis-generating in ferrets, clinical translation untested.
Gomoll et al. (1991) studied Myocardial injury resulting from ischemia/reperfusion. Monoclonal antibody (MoAb 60.3) was evaluated on Infarct size (33% and 45% reduction). Intravenous infusion of MoAb 60.3 at 2 mg/kg during occlusion reduced infarct size by 33% and 45% following 6 and 24 hours of reperfusion in a ferret model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: